Cancer drug may reveal HIV's secret brain hideout
NCT ID NCT03239899
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a single dose of pembrolizumab, a cancer drug, is safe for people with HIV who do not have cancer. The goal was to see if the drug could help reveal HIV hiding in the brain. Thirteen adults with well-controlled HIV participated. The study was not meant to treat HIV, but to learn more about where the virus may persist.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab
What this could lead to
If successful, this could help researchers understand where HIV hides in the brain, potentially pointing toward future strategies to eliminate the virus.
What could go wrong
This is a very early, small safety study with only 13 participants and a single dose. It is not designed to treat HIV, and pembrolizumab can cause serious immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States